BI 706321 clinical trials

A Phase IIa, randomised, double-blind, placebo-controlled trial to evaluate the safety, efficacy, pharmacokinetics and pharmacodynamics of BI 706321 orally administered for 12 weeks in patients with Crohn`s Disease (CD) receiving ustekinumab induction treatment

This study is looking into a new medication (BI 706321) for Crohn's disease. It aims to see if it's safe and effective when taken alongside an existing treatment called Stelara, and how it works in the body.